WO2021261564A1 - ジペプチドの製造法 - Google Patents
ジペプチドの製造法 Download PDFInfo
- Publication number
- WO2021261564A1 WO2021261564A1 PCT/JP2021/023994 JP2021023994W WO2021261564A1 WO 2021261564 A1 WO2021261564 A1 WO 2021261564A1 JP 2021023994 W JP2021023994 W JP 2021023994W WO 2021261564 A1 WO2021261564 A1 WO 2021261564A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- protein
- dipeptide
- acid sequence
- dna
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title claims abstract description 109
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 123
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 117
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 93
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 45
- 244000005700 microbiome Species 0.000 claims abstract description 39
- 239000000758 substrate Substances 0.000 claims abstract description 28
- 150000001413 amino acids Chemical group 0.000 claims description 137
- 235000018102 proteins Nutrition 0.000 claims description 111
- 108020004414 DNA Proteins 0.000 claims description 91
- 150000008575 L-amino acids Chemical class 0.000 claims description 65
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 48
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 45
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 39
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 36
- 102000004190 Enzymes Human genes 0.000 claims description 35
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 34
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 32
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 32
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 31
- 108020004511 Recombinant DNA Proteins 0.000 claims description 30
- 229940024606 amino acid Drugs 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 30
- 229960004452 methionine Drugs 0.000 claims description 30
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 29
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 29
- 229960003767 alanine Drugs 0.000 claims description 28
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 27
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 27
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 25
- 229930195722 L-methionine Natural products 0.000 claims description 25
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 24
- 229960001153 serine Drugs 0.000 claims description 22
- 108010021466 Mutant Proteins Proteins 0.000 claims description 21
- 102000008300 Mutant Proteins Human genes 0.000 claims description 21
- 239000004471 Glycine Substances 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 20
- 229960002449 glycine Drugs 0.000 claims description 19
- 229960005261 aspartic acid Drugs 0.000 claims description 18
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 17
- 229960002989 glutamic acid Drugs 0.000 claims description 17
- 229960003136 leucine Drugs 0.000 claims description 17
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 15
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 15
- 239000004395 L-leucine Substances 0.000 claims description 15
- 235000019454 L-leucine Nutrition 0.000 claims description 15
- 239000004473 Threonine Substances 0.000 claims description 15
- 239000012736 aqueous medium Substances 0.000 claims description 15
- 229960002885 histidine Drugs 0.000 claims description 15
- 229960002898 threonine Drugs 0.000 claims description 15
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
- 229960004441 tyrosine Drugs 0.000 claims description 14
- 229960002429 proline Drugs 0.000 claims description 13
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 12
- 229930182816 L-glutamine Natural products 0.000 claims description 12
- 229930182821 L-proline Natural products 0.000 claims description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- 229960004295 valine Drugs 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 229960002743 glutamine Drugs 0.000 claims description 11
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 10
- 229960005190 phenylalanine Drugs 0.000 claims description 10
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 229960004799 tryptophan Drugs 0.000 claims description 9
- 229930182844 L-isoleucine Natural products 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 5
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 70
- 239000006227 byproduct Substances 0.000 abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 description 53
- 241000588724 Escherichia coli Species 0.000 description 34
- 241000607720 Serratia Species 0.000 description 29
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 230000035772 mutation Effects 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 241000588722 Escherichia Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 101710128687 Alanine-anticapsin ligase Proteins 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 4
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 4
- -1 L. -Methionine Chemical compound 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229960002648 alanylglutamine Drugs 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 230000003313 weakening effect Effects 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 108010056243 alanylalanine Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 101100165111 Bacillus subtilis (strain 168) bacD gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241001452028 Escherichia coli DH1 Species 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 101150098466 rpsL gene Proteins 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical group OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FPXCYGSFMNEBPA-UHFFFAOYSA-N 1h-indole;prop-2-enoic acid Chemical compound OC(=O)C=C.C1=CC=C2NC=CC2=C1 FPXCYGSFMNEBPA-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000901842 Escherichia coli W Species 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 150000008539 L-glutamic acids Chemical class 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 241000186254 coryneform bacterium Species 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02028—L-Amino-acid alpha-ligase (6.3.2.28)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
Definitions
- Patent Document 5 shows that a dipeptide having a branched-chain amino acid on the N-terminal side is efficiently produced by modifying L-methionine at position 334 of the amino acid sequence of YwfE.
- Non-Patent Document 3 in the L-amino acid ligase TabS possessed by Pseudomonas syringae, when the 85th serine corresponding to the 110th amino acid residue in the amino acid sequence of YwfE is replaced with threonine, the synthetic activity of the prolyl glycine of TabS Has been shown to improve.
- the present invention relates to the following 1 to 8. 1.
- amino acid sequence represented by SEQ ID NO: 2 one or more amino acid residues selected from the group consisting of the 107th, 108th, and 110th amino acids are the amino acid residues described in [1] to [3] below, respectively.
- One or more amino acid residues thereof are proteins consisting of amino acid sequences substituted with the amino acid residues described in [1'] to [3'], respectively, and the substrate specificity is higher than that of the original protein.
- a protein with enhanced L-amino acid ⁇ -ligase activity [1'] From the group consisting of L-serine, L-alanine, L-histidine, L-glutamine, L-aspartic acid, L-glutamic acid, glycine and L-methionine for the 107th amino acid residue.
- the enzyme source and two L-amino acids are allowed to exist in an aqueous medium, and a dipeptide is produced and accumulated in the aqueous medium, and the dipeptide is produced from the aqueous medium.
- a method for producing a dipeptide which comprises collecting a dipeptide. 7.
- Production of a dipeptide which comprises culturing a microorganism capable of producing the protein according to 1 or 2 above in a medium, producing and accumulating a dipeptide in the culture, and collecting the dipeptide from the culture. Law. 8.
- the dipeptide is of formula (I) R 1- R 2 (I) (In the formula, R 1 is L-alanine, R 2 is L-glutamine, L-glutamic acid, glycine, L-valine, L-leucine, L-isoleucine, L-proline, L-phenylalanine, L-tryptophan, L- Represented by amino acid residues selected from methionine, L-serine, L-threonine, L-cysteine, L-aspartin, L-tyrosine, L-lysine, L-arginine, L-histidine and L-aspartic acid).
- amino acid residues selected from the group consisting of the 107th, 108th, and 110th amino acids are the amino acids according to the following [1] to [3], respectively.
- Residue [2] Consists of L-phenylalanine, L-methionine, L-serine, L-proline, L-threonine, L-alanine, L-tyrosine, glycine and L-leucine for the 108th amino acid residue.
- Amino acid residue selected from the group [3] A group consisting of L-methionine, L-valine, L-alanine, L-asparagin, L-cysteine, L-tryptophane and L-phenylalanine for the 110th amino acid residue.
- the original protein described in (2) above is the mutant protein described in [4] or the homologous protein described in [5].
- the amino acid residues corresponding to the 107th, 108th, and 110th positions of the amino acid sequence represented by SEQ ID NO: 2 are the amino acid sequence of the original protein and the amino acid of SEQ ID NO: 2. Refers to each amino acid residue that is aligned at the same position as the 107th, 108th, and 110th amino acid residues in the amino acid sequence of SEQ ID NO: 2 when aligned with the sequence.
- amino acid residues corresponding to the 107th, 108th, and 110th positions of the above are collectively referred to as "amino acid residues corresponding to the 107th, 108th, and 110th positions of the amino acid sequence represented by SEQ ID NO: 2.”
- amino acid sequence of the protein according to (1) or (2) above one or more selected from the group consisting of the amino acid residues corresponding to the 107th, 108th and 110th amino acid sequences represented by SEQ ID NO: 2.
- the fact that the amino acid residue is replaced with the amino acid residue described in (1) [1] to [3] or (2) [1'] to [3'] is the above (1) or (2).
- Amino acid sequence alignment can be created, for example, using the known alignment program ClustalW [Nucelic Acids Research 22,4673, (1994)].
- ClustalW is, for example, http: // www. ebi.ac. It can be used from uk / lustalw / (European Bioinformatics Institute). For example, default values can be used as parameters when creating an alignment using ClustalW.
- the amino acid residue corresponding to the 107th amino acid sequence represented by SEQ ID NO: 2 is preferably L-serine, L-alanine, L-histidine, glycine and among the amino acids of [1] or [1'] above. It is desirable to replace it with an amino acid residue selected from the group consisting of L-methionine, more preferably an amino acid residue selected from the group consisting of L-alanine, L-histidine and glycine.
- the amino acid residue corresponding to the 108th position of the amino acid sequence represented by SEQ ID NO: 2 is preferably L-phenylalanine, L-methionine, L-serine, L- among the amino acids of [2] or [2'] above.
- the amino acid residue corresponding to the 110th position of the amino acid sequence represented by SEQ ID NO: 2 is preferably L-methionine, L-cysteine, L-tryptophan and L- among the amino acids of the above [3] or [3']. It is desirable to replace it with an amino acid residue selected from the group consisting of phenylalanine, more preferably an amino acid residue selected from the group consisting of L-methionine, L-tryptophan and L-phenylalanine.
- the L-amino acid ⁇ -ligase activity refers to an activity in which ATP and two different types of L-amino acids are used as substrates to produce a dipeptide in which the two amino acids are peptide-bonded with a carboxyl group at the ⁇ -position.
- the L-amino acid also includes glycine having no character isomerism.
- L-Amino Acids As L-amino acids used as substrates for ⁇ -ligase active proteins, L-alanine, L-aspartin, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L- Examples include leucine, L-lysine, L-arginine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like. can.
- the protein according to (1) or (2) above has improved substrate specificity as compared with the original protein.
- a recombinant DNA having a DNA encoding the protein whose activity is to be confirmed is prepared by the method described later.
- the recombinant DNA is used to culture a microorganism obtained by transforming a microorganism having no L-amino acid ⁇ -ligase activity, for example, Escherichia coli W3110 strain, and cell extraction containing the protein from the obtained culture.
- the cell extract containing the protein is brought into contact with an aqueous solution containing the substrate ATP and two L-amino acids to generate a dipeptide in the aqueous solution.
- the substrate specificity is improved as compared with the original protein. You can confirm that.
- a mutant protein is a protein obtained by artificially deleting or substituting an amino acid residue in the original protein, or artificially inserting or adding an amino acid residue in the protein.
- an amino acid is deleted, substituted, inserted or added means that 1 to 20 amino acids are deleted, substituted or added at an arbitrary position in the amino acid sequence represented by SEQ ID NO: 2. It may be inserted or added, for example, 1 to 15, 1 to 10, 1 to 5 amino acids may be deleted, substituted, inserted or added.
- Amino acids to be substituted, inserted or added may be natural or non-natural.
- Natural amino acids include L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L. -Methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like can be mentioned.
- amino acids contained in the same group can be replaced with each other.
- Amino acids contained in the same group can be replaced with each other.
- Group A leucine, isoleucine, norleusin, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine
- Group B aspartic acid, glutamic acid, isoaspartic acid, Isoglutamic acid, 2-aminoadipic acid, 2-aminosveric acid
- Group C aspartic acid, glutamic acid D group: lysine, arginine, ornitine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid
- Group E proline, 3 -Hydroxyproline, 4-hydroxyproline
- F group serine, threonine, homoser
- It consists of a base sequence having at least 80% or more, preferably 90% or more, more preferably 95% or more, most preferably 98% or more identity with the base sequence represented by SEQ ID NO: 1, and L. -DNA encoding a mutant or homologous protein with amino acid ⁇ -ligase activity
- the various conditions described above can also be set by adding or changing the blocking reagent used to suppress the background of the hybridization experiment.
- the addition of the blocking reagent described above may be accompanied by a change in hybridization conditions in order to adapt the conditions.
- the DNA of the present invention uses, for example, a DNA encoding a protein having the amino acid sequence represented by SEQ ID NO: 2, and is located on the DNA at positions 107 and 108 of the amino acid sequence represented by SEQ ID NO: 2. And the base sequence of the part encoding one or more amino acid residues selected from the group consisting of the 110th corresponding amino acid residues, for example, Molecular Cloning 4th Edition (Cold Spring Harbor Laboratory Press (2012)) and Current. -Introduce a mutation by the site-specific mutagenesis method described in Protocols in Molecular Biology (JOHN WILEY & SONS, INC.), Etc., and replace it with a base sequence encoding another amino acid residue. Can be obtained by. Alternatively, the DNA of the present invention can also be obtained by using PrimeSTAR Mutagenesis Basal Kit (manufactured by Takara Bio Inc.) or the like.
- Vectors that can be used to determine the base sequence of the DNA of the present invention include pBluescriptII KS (+), pPCR-Script Amp SK (+) (all manufactured by Agilent Technologies), and pT7Blue (manufactured by Agilent Technologies). ), PCRII (manufactured by Thermo Fisher Scientific), pCR-TRAP (manufactured by Genehunter), and pDIRECT [Nucleic Acids Res. , 18, 6069 (1990)] and the like.
- Escherichia coli DH1 Escherichia coli MC1000, Escherichia coli W1485, Escherichia coli W3110, Escherichia coli MP347, Escherichia coli 22 etc.
- the recombinant DNA of the present invention is a DNA that can be autonomously replicated in a host cell, and the DNA of the present invention is incorporated into an expression vector containing a promoter at a position where the DNA of the present invention can be transcribed. DNA.
- DNA that can be incorporated into a chromosome in a host cell and has the DNA of the present invention is also the recombinant DNA of the present invention.
- the recombinant DNA of the present invention is a recombinant DNA composed of a promoter, a ribosome-binding sequence, the above-mentioned 2 DNA of the present invention, and a transcription termination sequence. Is preferable. In addition, genes that control promoters may be included.
- the expression vectors include, for example, pColdI, pSTV28, pUC118 (all manufactured by Takara Bio), pET21a, pCDF-1b, pRSF.
- pTrS30 [adjusted from Escherichia coli JM109 / pTrS30 (FERM BP-5407)]
- pTrS32 [adjusted from Escherichia coli JM109 / pTrS32 (FERM BP-5408)]
- pTK31 [AP AND ENVIRONMENTAL MICROBIOLOGY, 2007, Vol. 73, No. 20, p6378-6385]
- pPE167 Appl. Environ. Microbiol.
- the expression vectors include, for example, pCG1 (Japanese Patent Laid-Open No. 57-134500) and pCG2 (Japanese Patent Laid-Open No. 58-35197). , PCG4 (Japanese Patent Laid-Open No. 57-183799), pCG11 (Japanese Patent Laid-Open No.
- Protozoa such as D-0110, or Saccharomyces cerevisiae, Saccharomyces pombe, Kluyveromyces lactis, Trichosporon purlulans, Schizosaccharomyces pichia spp.
- a homologous recombination method As a method for incorporating recombinant DNA into the chromosome of a host cell, for example, a homologous recombination method can be mentioned.
- a homologous recombination method for example, a method using a plasmid for homologous recombination that can be produced by ligating with a plasmid DNA having a drug resistance gene that cannot autonomously replicate in the host cell to be introduced can be mentioned.
- a method using homologous recombination frequently used in Escherichia coli for example, a method of introducing recombinant DNA using a homologous recombination system of lambda phage [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].
- Selection method utilizing the fact that Escherichia coli becomes susceptible to streptomycin by [Mol. Microbiol. , 55, 137 (2005), Biosci. Biotechnol. Biochem. , 71,295 (2007)] and the like can be used to obtain Escherichia coli in which the target region on the chromosomal DNA of the host cell is replaced with recombinant DNA.
- the transformant obtained by the above method has the DNA of the present invention described in 2 above means that, for example, the transformant is cultured in a medium and the dipeptide of interest accumulated in the culture. Can be confirmed by comparing the amount of the strain produced with that of the parent strain.
- an extract containing the protein of the present invention is prepared from the culture, the extract is made to have two different L-amino acids present in an aqueous medium, and the amount of dipeptide accumulated in the aqueous medium is determined. , Can also be confirmed by comparing with that of the parent strain.
- the protein according to (1) or (2) is used as an enzyme source, the enzyme source and two kinds of L-amino acids are present in an aqueous medium, and a dipeptide is produced and accumulated in the aqueous medium.
- the dipeptide can be collected from the aqueous medium.
- the enzyme source may be the purified protein according to (1) or (2), or the transformant of 4 above, that is, the ability to produce the protein according to (1) or (2) above. It may be a culture obtained by culturing a microorganism having a protein in a medium or a processed product of the culture.
- ATP is present in the aqueous solvent together with the two L-amino acids.
- the culture includes the cultured microorganism having the ability to produce the protein according to (1) or (2) and the medium, and is expressed by the microorganism in the culture (the above).
- the protein according to 1) or (2) is contained.
- the above-mentioned culture or a processed product of the culture contains the protein and ATP according to (1) or (2) as an enzyme source.
- the processed product of the culture includes a concentrate of the culture, a dried product of the culture, a bacterial cell obtained by centrifuging the culture, a dried product of the bacterial cell, a frozen dried product of the bacterial cell, and the bacterial cell.
- the transformant of 4 above that is, a microorganism capable of producing the protein according to (1) or (2) above is cultured in a medium.
- a method for producing a dipeptide by a fermentation method which comprises producing and accumulating a dipeptide in a culture and collecting the dipeptide from the culture.
- the culture includes the cultured microorganism having the ability to produce the protein according to (1) or (2) and the medium, and is expressed by the microorganism in the culture (the above).
- the protein according to 1) or (2) is contained.
- the medium for culturing the transformant is a medium containing a carbon source, a nitrogen source, inorganic salts, etc. that can be assimilated by the transformant, and the transformant can be efficiently cultured.
- Natural medium or synthetic medium may be used.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1.配列番号2で表されるアミノ酸配列において、107番目、108番目及び110番目からなる群より選ばれる1以上のアミノ酸残基が、それぞれ以下の[1]~[3]に記載のアミノ酸残基に置換されたアミノ酸配列ならなる蛋白質であり、かつ、配列番号2で表されるアミノ酸配列を有する元となる蛋白質に比べて基質特異性が向上したL-アミノ酸αリガーゼ活性を有する蛋白質。
[1]107番目のアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2]108番目のアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3]110番目のアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基
2.以下の[4]又は[5]に記載の元となる蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の107番目、108番目及び110番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基が、それぞれ[1´]~[3´]に記載のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質であり、かつ、元となる蛋白質に比べて基質特異性が向上したL-アミノ酸αリガーゼ活性を有する蛋白質。
[1´]107番目に対応するアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2´]108番目に対応するアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3´]110番目に対応するアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基
[4]配列番号2で表されるアミノ酸配列のうち1~20個のアミノ酸残基が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する変異蛋白質
[5]配列番号2で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する相同蛋白質
3.上記1又は2に記載の蛋白質をコードするDNA。
4.上記3に記載のDNAを含有する組換え体DNA。
5.上記4に記載の組換え体DNAで宿主細胞を形質転換して得られる形質転換体。
6.上記1又は2に記載の蛋白質を酵素源として用い、該酵素源及び2種のL-アミノ酸を水性媒体中に存在せしめ、該水性媒体中にジペプチドを生成、蓄積させ、該水性媒体中からジペプチドを採取することを特徴とする、ジペプチドの製造法。
7.上記1又は2に記載の蛋白質を生産する能力を有する微生物を培地に培養し、培養物中にジペプチドを生成、蓄積せしめ、該培養物から該ジペプチドを採取することを特徴とする、ジペプチドの製造法。
8.ジペプチドが、式(I)
R1-R2 (I)
(式中、R1はL-アラニン、R2はL-グルタミン、L-グルタミン酸、グリシン、L-バリン、L-ロイシン、L-イソロイシン、L-プロリン、L-フェニルアラニン、L-トリプトファン、L-メチオニン、L-セリン、L-スレオニン、L-システイン、L-アスパラギン、L-チロシン、L-リジン、L-アルギニン、L-ヒスチジン及びL-アスパラギン酸から選ばれるアミノ酸残基を表す)で表されるジペプチドである、上記6又は7に記載の製造法。
本発明の蛋白質は、以下の(1)又は(2)に記載の蛋白質である。
[1]107番目のアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2]108番目のアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3]110番目のアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基
[1´]107番目に対応するアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2´]108番目に対応するアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3´]110番目に対応するアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基
[4]配列番号2で表されるアミノ酸配列のうち1~20個のアミノ酸が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する変異蛋白質。
[5]配列番号2で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する相同蛋白質。
A群:ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、o-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン
B群:アスパラギン酸、グルタミン酸、イソアスパラギン酸、イソグルタミン酸、2-アミノアジピン酸、2-アミノスベリン酸
C群:アスパラギン、グルタミン
D群:リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸
E群:プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン
F群:セリン、スレオニン、ホモセリン
G群:フェニルアラニン、チロシン
本発明のDNAは、上記(1)又は(2)に記載の蛋白質をコードするDNAである。
[6]配列番号1で表される塩基配列からなるDNA
[7]配列番号1で表される塩基配列と相補的な塩基配列からなるDNAとストリンジェンドな条件下でハイブリダイズし、かつ、L-アミノ酸αリガーゼ活性を有する変異タンパク質又は相同蛋白質をコードするDNA
[8]配列番号1で表される塩基配列と少なくとも80%以上、好ましくは90%以上、さらに好ましくは95%以上、最も好ましくは98%以上の同一性を有する塩基配列からなり、かつ、L-アミノ酸αリガーゼ活性を有する変異タンパク質又は相同蛋白質をコードするDNA
本発明の組換え体DNAは、宿主細胞において自律複製可能なDNAであって、上記2の本発明のDNAを転写できる位置にプロモーターを含有している発現ベクターに本発明のDNAが組み込まれているDNAである。
本発明の形質転換体は、上記3に記載の本発明の組換え体DNA、すなわち、上記2に記載の本発明のDNAを含有する組換え体DNAで宿主細胞を形質転換して得られる形質転換体である。
本発明のジペプチドの製造法は、以下の5-1及び5-2に記載の方法である。
本発明のジペプチドの製造法としては、2種のL-アミノ酸を前駆体として用いるジペプチドの製造法を挙げることができる。
本発明のジペプチドの製造法としては、上記4の形質転換体、すなわち、上記(1)又は(2)に記載の蛋白質を生産する能力を有する微生物を培地に培養し、培養物中にジペプチドを生成、蓄積させ、該培養物中からジペプチドを採取することを特徴とする、発酵法によるジペプチドの製造法を挙げることができる。ここで、培養物とは、培養された上記(1)若しくは(2)に記載の蛋白質を生産する能力を有する微生物及び培地を含むものであり、当該培養物中に微生物によって発現された上記(1)又は(2)に記載の蛋白質が含まれている。
R1-R2 (I)
(式中、R1はL-アラニン、R2はL-グルタミン、L-グルタミン酸、グリシン、L-バリン、L-ロイシン、L-イソロイシン、L-プロリン、L-フェニルアラニン、L-トリプトファン、L-メチオニン、L-セリン、L-スレオニン、L-システイン、L-アスパラギン、L-チロシン、L-リジン、L-アルギニン、L-ヒスチジン及びL-アスパラギン酸から選ばれるアミノ酸残基を表す)
で表されるジペプチドである。
実施例において、L-アラニル-L-グルタミン及びL-アラニル-L-アラニンの分析、定量は以下に示す手順に従い、HPLC(島津製作所社製)にて分析した。
分析条件
カラム:InertSustain 3μm 3mm×150mm(ジーエルサイエンス社製)
カラム温度:40℃
移動相:リン酸1カリウム4.08g/L、へプタンスルホン酸ナトリウム6.07g/L及びアセトニトリル125mL/L(pH2.5、リン酸で調整)
流速:0.4mL/分
検出波長:210nm
(1)バチルス・サチルス 168株由来L-アミノ酸αリガーゼ(YwfE)発現ベクターの調製
定法により調製したバチルス・サチルス 168株のゲノムDNAを鋳型として、配列番号4及び5で表される塩基配列からなるDNAをプライマーセットとしてPCRを行い、ywfE遺伝子を含む約1.4kbpのDNA断片を得た。
上記(1)で得られたプラスミドpET21a-ywfEを鋳型とし、PrimeSTAR Mutagenesis Basal Kit(タカラバイオ社製)を用いて、表1~3のいずれかに記載の「プライマーセット」で表される塩基配列からなるDNAをプライマーセットとして、YwfEのアミノ酸配列上の107番目、108番目又は110番目のいずれかのアミノ酸残基を他のアミノ酸に置換した全57種類のプラスミドを造成した。
上記実施例1で得られた計58種の形質転換体をLBプレート上で30℃にて24時間培養し、100mg/Lのアンピシリンを含むLB培地5mLが入った大型試験管に植菌して30℃で20時間、振盪培養した。その後、得られた培養液を、100mg/Lのアンピシリンを含むLB培地50mLが入ったフラスコに0.1mL植菌し、30℃で振盪培養した。菌体OD600が0.4~0.6の範囲に達した後、イソプロピル-β-D-チオガラクトピラノシド(IPTG)を終濃度0.5mMになるよう添加し、更に6時間振盪培養した。培養終了後、培養液を遠心分離して菌体を取得した。
上記で得た野生型YwfE精製酵素、及び、YwfEのアミノ酸配列上の107番目のL-Asnを上記表1に記載のアミノ酸残基に置換した変異型YwfEの精製酵素計19種を用いて、酵素反応によるL-Ala-L-Glnの生成検討を実施した。
上記で得た野生型YwfE精製酵素、及び、YwfEのアミノ酸配列上の108番目のL-Asnを上記表2に記載のアミノ酸残基に置換した変異型YwfEの精製酵素計19種を用いて、酵素反応によるL-Ala-L-Glnの生成検討を実施した。
上記で得た野生型YwfE精製酵素、及び、YwfEのアミノ酸配列上の110番目のL-Leuを上記表3に記載のアミノ酸残基に置換した変異型YwfEの精製酵素計19種を用いて、酵素反応によるL-Ala-L-Glnの生成検討を実施した。
(1)微生物の造成
野生型YwfEを含む非特許文献2に記載のプラスミドpPE167を鋳型とし、PrimeSTAR Mutagenesis Basal Kit(タカラバイオ社製)を用いて、表7に記載の「プライマーセット」で表される塩基配列からなるDNAをプライマーセットとして、YwfEのアミノ酸配列上の107番目、108番目又は110番目のいずれかのアミノ酸を他のアミノ酸に置換した、全10種類の変異型YwfE発現プラスミドを造成した。
得られた形質転換体を100mg/Lのカナマイシンを含むLBプレート上で30℃にて24時間培養し、10g/Lのグルコース及び100mg/Lのカナマイシンを含むLB培地5mLが入った太型試験管に植菌して30℃で20時間、振盪培養した。その後、得られた培養液を、100mg/Lのカナマイシンを含む生産培地[グルコース30g/L、硫酸マグネシウム七水和物1g/L、カザミノ酸5g/L、硫酸アンモニウム2g/L、リン酸水素二カリウム16g/L、リン酸二水素カリウム14g/L、クエン酸三ナトリウム二水和物1g/L、L-プロリン0.4g/L、チアミン塩酸塩10mg/L、硫酸第一鉄七水和物50mg/L、硫酸マンガン五水和物10mg/L(グルコース及び硫酸マグネシウム七水和物以外については、水酸化ナトリウム水溶液によりpH7.2に調整した後オートクレーブし、グルコース及び硫酸マグネシウム七水和物含有水溶液は別途調製した後オートクレーブし、それぞれ冷却後、混合した)]が5mL入った太型試験管に0.1mL植菌し、30℃で48時間振盪培養した。
Claims (8)
- 配列番号2で表されるアミノ酸配列において、107番目、108番目及び110番目からなる群より選ばれる1以上のアミノ酸残基が、それぞれ以下の[1]~[3]に記載のアミノ酸残基に置換されたアミノ酸配列ならなる蛋白質であり、かつ、配列番号2で表されるアミノ酸配列を有する元となる蛋白質に比べて基質特異性が向上したL-アミノ酸αリガーゼ活性を有する蛋白質。
[1]107番目のアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2]108番目のアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3]110番目のアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基 - 以下の[4]又は[5]に記載の元となる蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の107番目、108番目及び110番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基が、それぞれ[1´]~[3´]に記載のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質であり、かつ、元となる蛋白質に比べて基質特異性が向上したL-アミノ酸αリガーゼ活性を有する蛋白質。
[1´]107番目に対応するアミノ酸残基に対して、L-セリン、L-アラニン、L-ヒスチジン、L-グルタミン、L-アスパラギン酸、L-グルタミン酸、グリシン及びL-メチオニンからなる群より選ばれるアミノ酸残基
[2´]108番目に対応するアミノ酸残基に対して、L-フェニルアラニン、L-メチオニン、L-セリン、L-プロリン、L-スレオニン、L-アラニン、L-チロシン、グリシン及びL-ロイシンからなる群より選ばれるアミノ酸残基
[3´]110番目に対応するアミノ酸残基に対して、L-メチオニン、L-バリン、L-アラニン、L-アスパラギン、L-システイン、L-トリプトファン及びL-フェニルアラニンからなる群より選ばれるアミノ酸残基
[4]配列番号2で表されるアミノ酸配列のうち1~20個のアミノ酸残基が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する変異蛋白質
[5]配列番号2で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、L-アミノ酸αリガーゼ活性を有する相同蛋白質 - 請求項1又は2に記載の蛋白質をコードするDNA。
- 請求項3に記載のDNAを含有する組換え体DNA。
- 請求項4に記載の組換え体DNAで宿主細胞を形質転換して得られる形質転換体。
- 請求項1又は2に記載の蛋白質を酵素源として用い、該酵素源及び2種のL-アミノ酸を水性媒体中に存在せしめ、該水性媒体中にジペプチドを生成、蓄積させ、該水性媒体中からジペプチドを採取することを特徴とする、ジペプチドの製造法。
- 請求項1又は2に記載の蛋白質を生産する能力を有する微生物を培地に培養し、培養物中にジペプチドを生成、蓄積せしめ、該培養物から該ジペプチドを採取することを特徴とする、ジペプチドの製造法。
- ジペプチドが、式(I)
R1-R2 (I)
(式中、R1はL-アラニン、R2はL-グルタミン、L-グルタミン酸、グリシン、L-バリン、L-ロイシン、L-イソロイシン、L-プロリン、L-フェニルアラニン、L-トリプトファン、L-メチオニン、L-セリン、L-スレオニン、L-システイン、L-アスパラギン、L-チロシン、L-リジン、L-アルギニン、L-ヒスチジン及びL-アスパラギン酸から選ばれるアミノ酸残基を表す)
で表されるジペプチドである、請求項6又は7に記載の製造法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180035259.8A CN115667517A (zh) | 2020-06-25 | 2021-06-24 | 二肽的制造方法 |
JP2022532542A JPWO2021261564A1 (ja) | 2020-06-25 | 2021-06-24 | |
EP21828935.3A EP4166565A4 (en) | 2020-06-25 | 2021-06-24 | METHOD FOR DIPEPTIDE PRODUCTION |
US18/002,349 US20240141402A1 (en) | 2020-06-25 | 2021-06-24 | Method for producing dipeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020109616 | 2020-06-25 | ||
JP2020-109616 | 2020-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021261564A1 true WO2021261564A1 (ja) | 2021-12-30 |
Family
ID=79281349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/023994 WO2021261564A1 (ja) | 2020-06-25 | 2021-06-24 | ジペプチドの製造法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240141402A1 (ja) |
EP (1) | EP4166565A4 (ja) |
JP (1) | JPWO2021261564A1 (ja) |
CN (1) | CN115667517A (ja) |
WO (1) | WO2021261564A1 (ja) |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
WO2004058960A1 (ja) | 2002-12-26 | 2004-07-15 | Kyowa Hakko Kogyo Co., Ltd. | ジペプチドの製造法 |
JP2013081407A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081405A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081406A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081404A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2018102287A (ja) | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
CN110777123A (zh) * | 2019-12-04 | 2020-02-11 | 深圳瑞德林生物技术有限公司 | 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺 |
CN112175916A (zh) * | 2020-09-10 | 2021-01-05 | 济宁医学院 | 一种l-氨基酸连接酶突变体、重组载体、重组菌及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704036B2 (en) * | 2016-12-27 | 2020-07-07 | Tokai Bussan Co., Ltd. | Protein having synthetic activity for imidazole dipeptid and production method of imidazole dipeptide |
JP2020022433A (ja) * | 2018-08-01 | 2020-02-13 | 東海物産株式会社 | イミダゾールジペプチドの製造方法 |
-
2021
- 2021-06-24 JP JP2022532542A patent/JPWO2021261564A1/ja active Pending
- 2021-06-24 US US18/002,349 patent/US20240141402A1/en active Pending
- 2021-06-24 CN CN202180035259.8A patent/CN115667517A/zh active Pending
- 2021-06-24 WO PCT/JP2021/023994 patent/WO2021261564A1/ja active Application Filing
- 2021-06-24 EP EP21828935.3A patent/EP4166565A4/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
WO2004058960A1 (ja) | 2002-12-26 | 2004-07-15 | Kyowa Hakko Kogyo Co., Ltd. | ジペプチドの製造法 |
JP2013081407A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081405A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081406A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2013081404A (ja) | 2011-10-07 | 2013-05-09 | Kyowa Hakko Bio Co Ltd | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 |
JP2018102287A (ja) | 2016-12-27 | 2018-07-05 | 東海物産株式会社 | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 |
CN110777123A (zh) * | 2019-12-04 | 2020-02-11 | 深圳瑞德林生物技术有限公司 | 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺 |
CN112175916A (zh) * | 2020-09-10 | 2021-01-05 | 济宁医学院 | 一种l-氨基酸连接酶突变体、重组载体、重组菌及其应用 |
Non-Patent Citations (30)
Title |
---|
"Immunology methods manual", 1997, ACADEMIC PRESS |
"Methods for General and Molecular Bacteriology", 1994, ASM PRESS |
"Molecular Cloning", 2012, COLD SPRING HARBOR LABORATORY PRESS |
"Uniprot KB", Database accession no. Q8KWS8 |
AGRIC. BIOL. CHEM., vol. 48, 1984, pages 669 |
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277 |
APPL ENVIRON MICROBIOL, vol. 73, no. 20, 2007, pages 6378 - 6385 |
APPL. ENVIRON. MICROBIOL., vol. 73, 2007, pages 6378 - 6385 |
APPL. MICROBIOL. BIOTECHNOL., vol. 53, 2000, pages 674 - 679 |
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 20, 2007, pages 6378 - 6385 |
BIOSCI. BIOTECHNOL. BIOCHEM., vol. 71, 2007, pages 2905 |
CLUSTALW, NUCLEIC ACIDS RESEARCH, vol. 22, 1994, pages 4673 |
GENE, vol. 33, 1985, pages 103 |
HARUKA KINO: "Effective production of Pro-Gly by mutagenesis of l-amino acid ligase", J. BIOSCI. BIOEN., vol. 122, no. 2, 2016, pages 155 - 159, XP029621582, DOI: 10.1016/j.jbiosc.2016.01.014 |
J. BACTERIOL., vol. 153, 1983, pages 163 |
J. MOL. BIOL., vol. 215, 1990, pages 403 |
KARLINALTSCHUL, PRO. NAT. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
KAZUHIKO TABATA ET AL.: "Fermentative Production of L-Alanyl-L-Glutamine by a Metabolically Engineered Escherichia coli Strain Expressing L-Amino Acid a-Ligase", APPL. ENVIRON. MICROBIOL., vol. 73, no. 20, 2007, pages 6378 - 6385, XP007912741, DOI: 10.1128/AEM.01249-07 |
KAZUHIKO TABATA ET AL.: "ywfE in Bacillus subtilis Codes for a Novel Enzyme, L-Amino Acid Ligase", J. BACTERIOL., vol. 187, 2005, pages 5195 - 5202, XP002471715, DOI: 10.1128/jb.187.15.5195-5202.2005 |
METHODS ENZYMOL., vol. 183, 1990, pages 63 |
MOL. MICROBIOL., vol. 55, 2005, pages 137 |
NUCLEIC ACIDS RES., vol. 16, 1988, pages 6127 |
NUCLEIC ACIDS RES., vol. 18, 1990, pages 6069 |
PROC. NAT. ACA. SCI., USA, vol. 74, 1977, pages 5463 |
PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 6641 - 6645 |
PROC. NATL. ACAD. SCI., USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD. SCI., USA, vol. 81, 1984, pages 4889 |
PROC. NATL. ACAD. SCI., USA, vol. 82, 1985, pages 4306 |
See also references of EP4166565A4 |
YASUHITO SHOMURA: "Structural and enzymatic characterization of BacD, an L-amino acid dipeptide ligase from Bacillus subtilis", PROTEIN SCIENCE, vol. 21, 2012, pages 707 - 716, XP055817260, DOI: 10.1002/pro.2058 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021261564A1 (ja) | 2021-12-30 |
CN115667517A (zh) | 2023-01-31 |
EP4166565A1 (en) | 2023-04-19 |
US20240141402A1 (en) | 2024-05-02 |
EP4166565A4 (en) | 2024-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4881739B2 (ja) | L−アルギニン、l−オルニチンまたはl−シトルリンの製造法 | |
EP2489741B1 (en) | Method for production of glutathione or gamma-glutamylcysteine | |
JP6993227B2 (ja) | 希少糖の製造法 | |
JP2017523787A (ja) | フィードバック抵抗性アセトヒドロキシ酸シンターゼ変異体及びそれを用いたl−バリンの生産方法 | |
JP7035024B2 (ja) | テアニンの製造方法 | |
JP6934774B2 (ja) | イミダゾールジペプチド合成活性を有するタンパク質及びイミダゾールジペプチドの製造方法 | |
JP5951953B2 (ja) | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 | |
WO2022168992A1 (ja) | 1,3-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 | |
JP2013081404A (ja) | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 | |
JP4731327B2 (ja) | ジペプチドの製造法 | |
WO2021261564A1 (ja) | ジペプチドの製造法 | |
EP4400588A1 (en) | Recombinant microorganism used for producing cdp-choline, and method for producing cdp-choline using said recombinant microorganism | |
JP2013081406A (ja) | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 | |
JP2013081407A (ja) | 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法 | |
JP2021191241A (ja) | β−ポリリンゴ酸の製造法 | |
WO2024005155A1 (ja) | 4-(アミノメチル)シクロヘキサン-1-カルボン酸の製造方法 | |
JP2022001556A (ja) | 蛋白質及び3−ヒドロキシイソ吉草酸の製造方法 | |
WO2021125245A1 (ja) | 改変されたラクトースパーミアーゼを有する微生物及びラクトース含有オリゴ糖の製造法 | |
WO2023210244A1 (ja) | Nampt活性を有する蛋白質およびnmnの製造方法 | |
JP2022045001A (ja) | バリオールアミン及びボグリボースの製造方法 | |
JP2021019518A (ja) | ビオラセイン又はデオキシビオラセインの製造法 | |
WO2022176994A1 (ja) | 改変されたα1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 | |
WO2011083860A1 (ja) | L-アミノ酸の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828935 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022532542 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18002349 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2021828935 Country of ref document: EP Effective date: 20230116 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |